August 2017 | Targeted Therapies in Oncology

Improving Upon Exciting Radionuclide Therapy in Neuroendocrine Tumors

August 18, 2017

Clinical Articles

There is a great deal of excitement in the oncology field over the use of peptide receptor radionuclide therapy with lutetium-177 (177Lu)-octreotate (177 Lu-Dotatate, Lutathera) for the treatment of patients with neuroendocrine tumors. The treatment is being explored in potential combinations with other modalities, including with systemic treatment with PARP inhibitors, in this patient population.

Genomic Landscape of Prostate Cancer Aligns With Breast Cancer Subtypes

August 17, 2017

Clinical Articles

An analysis of the genomic landscape of patients with prostate cancer shows that tumors separated into 3 clusters that aligned with the luminal A, luminal B, and basal subtypes found in breast cancer tumors, according to a presentation during the 2017 American Urological Association Annual Meeting.

CAR T-Cell Therapies for Hematologic Malignancies Moving Toward the Clinic

August 16, 2017

Clinical Articles

Development of chimeric antigen receptor T-cell therapies is in the works for both hematologic malignancies and solid tumors, but the most promising results to date have been seen with CD19-targeted CAR T cells in the treatment of B-cell acute lymphoblastic leukemia.

Liquid Biopsies May Never Replace Tissue Biopsies, Wistuba Says

August 14, 2017

Clinical Articles

Tissue samples will continue to be necessary in the practice of immunotherapy as more biomarkers for cancer become known, and solid biopsies remain the prime means of assessing the presence of cancer, says Ignacio I. Wistuba, MD.